Synopsis: Recent reports suggest apolipoprotein B (ApoB) is a good predictor of coronary risk.
Low-density lipoprotein cholesterol (LDL-C) may underestimate the number of atherogenic
particles in certain patients with elevated levels of small dense LDL particles and
remnant particles. To this end, the American Diabetes Association/American College
of Cardiology treatment guidelines for cardiometabolic patients, including patients
with diabetes, recommend ApoB targets <90 mg/dL and <80 mg/dL for high-risk and very
high-risk patients, respectively.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Clinical LipidologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
103
Identification
Copyright
© 2011 Published by Elsevier Inc.
